Insider Buying: Immunome, Inc. (NASDAQ:IMNM) CTO Purchases 21,000 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 21,000 shares of Immunome stock in a transaction that occurred on Thursday, November 21st. The shares were acquired at an average price of $9.43 per share, for a total transaction of $198,030.00. Following the completion of the transaction, the chief technology officer now directly owns 21,000 shares of the company’s stock, valued at $198,030. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Immunome Stock Up 11.8 %

Shares of NASDAQ IMNM traded up $1.16 during trading on Monday, reaching $10.98. 351,854 shares of the stock were exchanged, compared to its average volume of 771,478. The company has a market capitalization of $685.37 million, a price-to-earnings ratio of -1.35 and a beta of 1.82. The business’s 50-day moving average price is $12.58 and its 200 day moving average price is $13.58. Immunome, Inc. has a twelve month low of $6.93 and a twelve month high of $30.96.

Wall Street Analysts Forecast Growth

IMNM has been the subject of several research reports. Stephens assumed coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective for the company. Wedbush reissued an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a research report on Friday, October 25th. Finally, Piper Sandler reduced their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $28.83.

Hedge Funds Weigh In On Immunome

Institutional investors have recently added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Immunome by 125.9% during the third quarter. Barclays PLC now owns 105,886 shares of the company’s stock worth $1,547,000 after acquiring an additional 59,016 shares during the last quarter. Geode Capital Management LLC grew its stake in Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after purchasing an additional 144,557 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Immunome in the 3rd quarter valued at approximately $363,000. Wellington Management Group LLP boosted its stake in shares of Immunome by 137.1% during the 3rd quarter. Wellington Management Group LLP now owns 140,690 shares of the company’s stock valued at $2,057,000 after buying an additional 81,354 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in shares of Immunome by 22.2% during the third quarter. Point72 Asset Management L.P. now owns 470,647 shares of the company’s stock worth $6,881,000 after buying an additional 85,580 shares in the last quarter. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.